[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"haploidentical-hematopoietic-stem-cell-transplantation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:haploidentical-hematopoietic-stem-cell-transplantation":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,40,65,91],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100644427","cousin-vs-sibling-donors-in-haplo-hsct-100644427",false,"NCT07662382","Cousin vs. Sibling Donors in Haplo-HSCT","Comparison of Outcomes of Haploidentical Hematopoietic Stem Cell Transplantation From Cousin Donors Versus Sibling Donors in Patients With Hematological Malignancies: A Target Trial Emulation Study","Inclusion Criteria:\n\n* Adult patients diagnosed with hematological malignancies, including acute leukemia (AL), chronic myeloid leukemia (CML), myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), and non-Hodgkin lymphoma (NHL)\n* Receipt of first haploidentical hematopoietic stem cell transplantation between 2017 and 2024\n* Documented exact date of transplantation available in medical charts\n* Verifiable donor kinship classified as either cousin or sibiling\n* Complete longitudinal follow-up data accessible for outcome assessment\n\nExclusion Criteria:\n\n* Prior receipt of any form of hematopoietic stem cell transplantation\n* An age difference of more than 18 years between the donor and recipient\n* Failure of successful infusion of donor-derived hematopoietic stem cells following conditioning regimen","ALL","18 Years",{"count":19,"type":20},1000,"ESTIMATED","OBSERVATIONAL","This observational study aims to emulate a hypothetical pragmatic, multicenter, non-blinded clinical trial enrolling adult patients undergoing haploidentical hematopoietic stem cell transplantation (haplo-HSCT) with grafts derived from either cousin or sibiling donors.\n\nThe main research question is whether cousin donor-derived haplo-HSCT is associated with inferior clinical outcomes relative to sibling donor-derived haplo-HSCT.\n\nStudy participants consist of adult patients diagnosed with hematological malignancies who underwent cousin or sibiling haplo-HSCT between 2017 and 2024, and all eligible recipients will receive regular follow-up assessments.",[24,25,26],"Hematopoietic Malignancies","Haploidentical Hematopoietic Stem Cell Transplantation","Donor","NOT_YET_RECRUITING","2026-06-16",{"date":30,"type":31},"2026-06-23","ACTUAL",{"date":33,"type":20},"2026-08-01",{"date":35,"type":20},"2027-10-31",{"name":37,"class":38},"The First Affiliated Hospital of Soochow University","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":47,"targetDuration":49,"studyType":21,"phases":4,"briefSummary":50,"conditions":51,"keywords":52,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":39},"100519311","haploidentical-hematopoietic-stem-cell-transplantation-with-early-atg-and-low-dose-post-transplant-cyclophosphamide-100519311","NCT06041893","Haploidentical Hematopoietic Stem Cell Transplantation With Early ATG and Low Dose Post-transplant Cyclophosphamide","Haploidentical Hematopoietic Stem Cell Transplantation With Early Antithymocyte Globulin and Low Dose Post-transplant Cyclophosphamide","Inclusion Criteria:\n\n* Patients undergoing haploidentical hematopoietic stem cell transplantation with ATG and low-dose post-transplant cyclophosphamide conditioning at the department of pediatrics, Samsung Medical Center.\n\nExclusion Criteria:\n\n* A clinical trial subject (legal representative, if applicable) who do not consent or is unable to give written consent.",{"count":48,"type":20},20,"1 Year","Aim of this study is to investigate the effect of early administration of anti-thymocyte globulin and post-transplant low-dose cyclophosphamide in heploidentical hematopoietic stem cell transplantation.",[25],[53,54],"post transplant cyclophosphamide","antithymocyte globulin","RECRUITING","2024-12-02",{"date":58,"type":31},"2024-12-03",{"date":60,"type":31},"2023-05-29",{"date":62,"type":20},"2025-12-31",{"name":64,"class":38},"Samsung Medical Center",{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":16,"minAge":72,"maxAge":17,"enrollmentInfo":73,"targetDuration":4,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":87,"leadSponsor":89,"locationsCount":39},"100548602","prospective-clinical-trial-for-children-with-tcr-depleted-vs-traditional-haplo-identicle-hsct-100548602","NCT06423131","Prospective Clinical Trial for Children With TCRαβ Depleted vs Traditional Haplo Identicle HSCT","TCRαβ+ Cell Deleted Versus Traditional Haploidentical Hematopoietic Stem Cell Transplantation ：A Single-center, Prospective, Non-randomized Controlled Clinical Study","Inclusion Criteria:\n\n* Age 8 weeks to 18 years\n* Children who meet the indicators haploidentical hematopoietic cell transplantation\n* No HLA ≥ 9\u002F10 donor or not suitable for this type of donor due to illness\n* Informed consent must be signed (by the patient or legal representative)\n\nExclusion Criteria:\n\n* Liver function abnormalities with bilirubin \\>2 mg\u002FdL and elevation of transaminases higher than 400 U\u002FL\n* Chronic active viral hepatitis\n* Ejection fraction \\\u003C50%\n* Respiratory failure necessitating supplemental oxygen\n* Patients with a history of psychiatric illness or a condition which could interfere with their ability to understand the requirements of the study\n* Patients unwilling or unable to comply with the protocol or unable to give informed consent\n* Concurrent severe or uncontrolled infection","8 Weeks",{"count":74,"type":20},110,"INTERVENTIONAL",[77],"NA","This is a single-center prospective, non-randomized controlled clinical study in China using CliniMACS TCRα\u002Fβ+ cell depleted stem cell haploidentical donors versus conventional Beijing protocol for haploidentical hematopoietic stem cell transplantation in children.",[80,81,82,25],"Graft-Versus-Host Disease","Hematopoietic Stem Cell Transplantation","Child, Only","2024-05-26",{"date":85,"type":31},"2024-05-29",{"date":83,"type":31},{"date":88,"type":20},"2028-03-31",{"name":90,"class":38},"Sijia Gu",{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":75,"phases":100,"briefSummary":102,"conditions":103,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":112,"locationsCount":39},"100545431","phase-3-haplo-cord-hct-vs-haplo-hct-for-t-all-patients-100545431","NCT06381817","Haplo-cord HCT vs. Haplo-HCT for T-ALL Patients","Haploidentical Hematopoietic Cell Transplantation Combined With an Unrelated Cord Blood Unit for Acute T Cell Lymphoblastic Leukemia Compared to Haploidentical Hematopoietic Cell Transplantation: a Multicenter, Randomized, Open-label Trial","Inclusion Criteria:\n\n* Patients with acute T cell lymphoblastic leukemia\n* With available minimal residual disease parameters assessed by flow cytometry and\u002For quantitative polymerase chain reaction\n* Willing to undergo haploidentical hematopoietic cell transplantation and having a suitable haploidentical donor\n* With Eastern Cooperative Oncology Group (ECOG) performance status of 0-3\n* Signing an informed consent form, having the ability to comply with study and follow-up procedures\n\nExclusion Criteria:\n\n* With other malignancies\n* Failing to acquire a suitable unrelated cord blood unit\n* With a previous history of autologous hematopoietic cell transplantation, allogeneic hematopoietic cell transplantation or chimeric antigen receptor T cell therapy\n* With uncontrolled infection intolerant to haploidentical hematopoietic cell transplantation\n* With severe organ dysfunction\n* In pregnancy or lactation period\n* With any conditions not suitable for the trial (investigators' decision)",{"count":99,"type":20},146,[101],"PHASE3","The goal of this clinical trial is to learn if haploidentical hematopoietic cell transplantation combined with an unrelated cord blood unit (haplo-cord HCT) works to treat acute T cell lymphoblastic leukemia (T-ALL). It will also learn about the safety of the transplantation. The main questions it aims to answer are:\n\nDose co-infusion of cord blood in haploidentical hematopoietic cell transplantation (haplo-HCT) lower the rate of relapse? What medical problems do participants have when having haplo-cord HCT? Researchers will compare haplo-cord HCT to haplo-HCT to see if haplo-cord HCT works to treat T-ALL.\n\nParticipants will be infused an unrelated cord blood unit at the same day of haploidentical graft infusion.",[104,25,105],"Acute T Cell Lymphoblastic Leukemia","Cord Blood","2024-04-24",{"date":108,"type":31},"2024-04-26",{"date":110,"type":31},"2024-04-01",{"date":88,"type":20},{"name":37,"class":38}]